– AstraZeneca and Care Access Research are teaming up to
provide decentralized, mobile research site operations for AstraZeneca’s
AZD7442 phase III clinical trial in the US.
– The Phase III clinical trial called STORM CHASER will
assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and
pre-emptive treatment in approximately 1,125 participants in the US and UK.
Care Access Research, a decentralized research organization
(DRO) that operates as one connected team of physicians and research experts,
today announced a collaboration with global biopharmaceutical company AstraZeneca to accelerate a clinical
trial in the US for AZD7442, AstraZeneca’s long-acting monoclonal antibody
(LAAB) combination for the potential prevention of COVID-19.
STORM CHASER Clinical Trial for COVID-19 Long-Acting
Antibody Combination
Care Access is supporting the Phase III clinical trial
called STORM CHASER, which will assess the safety and efficacy of AZD7442 for
post-exposure prophylaxis and pre-emptive treatment in approximately 1,125
participants in the US and UK. Participants in this trial will include adults over
18 years of age following exposure to SARS-COV-2 and who are therefore at
appreciable risk of developing COVID-19. The trial will include people living
or working at long-term care facilities as well as industrial and military
settings.
The Care Access and AstraZeneca teams are collaborating to
rapidly develop, deploy, and manage clinical research sites across the country,
using Care Access’ innovative Mobile Sites On Demand capability to bring
research capabilities – including people, equipment, software, and processes –
to places and communities that would otherwise have limited access to clinical
trials, such as long term care facilities. Care Access is uniquely equipped
with the operational systems and staff required to mobilize the entire clinical
research operation and bring it directly to patients.
“We are excited to collaborate with Care Access and leverage their unique decentralized, mobile model for this important Phase III trial for AZD7442 in the US,” said Mark Esser, Vice President, Microbial Sciences BioPharmaceuticals R&D, AstraZeneca. “AZD7442 has the potential to be an important preventative and therapeutic medicine against COVID-19.”
